Viatris Inc. (VTRS): Price and Financial Metrics
VTRS Price/Volume Stats
| Current price | $11.25 | 52-week high | $13.62 |
| Prev. close | $11.12 | 52-week low | $8.74 |
| Day low | $11.10 | Volume | 4,679,800 |
| Day high | $11.31 | Avg. volume | 9,485,208 |
| 50-day MA | $12.08 | Dividend yield | 4.32% |
| 200-day MA | $10.74 | Market Cap | 13.50B |
VTRS Stock Price Chart Interactive Chart >
Viatris Inc. (VTRS) Company Bio
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania. The company was formed through the merger of Mylan and Upjohn, a division of Pfizer, on November 16, 2020. (Source:Wikipedia)
Latest VTRS News From Around the Web
Below are the latest news stories about VIATRIS INC that investors may wish to consider to help them evaluate VTRS as an investment opportunity.
Regeneron Gains After Eye-Drug Patent Victory Over Viatris(Bloomberg) -- Regeneron Pharmaceuticals Inc. rose the most in almost two months after a court ruled that the drugmaker’s patent rights were infringed by a cheaper copy of its eye drug developed by Viatris Inc. Most Read from BloombergThe Late-Night Email to Tim Cook That Set the Apple Watch Saga in MotionChinese Carmaker Overtakes Tesla as World’s Most Popular EV MakerBridgewater CEO’s Past Office Romance Led to Favoritism ClaimsXiaomi Unveils Its First EV, With Ambition to Be China’s Porsche o |
Viatris to Participate in 42nd Annual J.P. Morgan Healthcare ConferenceViatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024. Chief Executive Officer Scott A. Smith, President Rajiv Malik and Chief Financial Officer Sanjeev Narula will represent the company in a presentation followed by a fireside chat scheduled at 10:30 a.m. PST / 1:30 p.m. ET. |
Why Investors Need to Take Advantage of These 2 Medical Stocks NowInvestors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP. |
UPDATE 1-Drugmaker Viatris appoints Theodora Mistras as CFOGlobal healthcare company Viatris on Friday appointed Theodora Mistras as its chief financial officer, effective March 1. The company said the current CFO Sanjeev Narula will work closely with Mistras to support a smooth transition and will then depart the company on March 1. Mistras most recently was the managing director of healthcare investment banking at Citigroup Global Markets and has almost two decades of leadership, advisory and capital markets experience, Viatris said. |
Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D OfficerViatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that, as it prepares to enter Phase 2 of its strategic plan, Theodora "Doretta" Mistras has been appointed Chief Financial Officer (CFO) effective March 1, 2024, and Philippe Martin has been appointed Chief R&D Officer with immediate effect. |
VTRS Price Returns
| 1-mo | -6.33% |
| 3-mo | -0.35% |
| 6-mo | 29.01% |
| 1-year | 22.10% |
| 3-year | -4.48% |
| 5-year | -52.45% |
| YTD | 4.90% |
| 2023 | 2.06% |
| 2022 | -14.29% |
| 2021 | -26.12% |
| 2020 | -6.77% |
| 2019 | -26.64% |
VTRS Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Loading social stream, please wait...